Sequenom könnte heute rennen !!! - 500 Beiträge pro Seite

[lassevegas]

Wednesday August 29, 2:00 am Eastern Time
Press Release
SOURCE: SEQUENOM, Inc.
SEQUENOM and GlaxoSmithKline Join Forces to Generate Genome-Wide SNP Assay Portfolio
SAN DIEGO, Aug. 29 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM - news) today announced that it has entered into a multimillion dollar agreement with GlaxoSmithKline (GSK). GSK will participate in SEQUENOM`s ongoing project to generate a genome-wide single nucleotide polymorphism (SNP) assay portfolio to screen the human genome for genes associated with diseases and adverse drug reactions. This confirmed and validated SNP assay portfolio, together with a high-performance genotyping platform such as SEQUENOM`s MassARRAY(TM) technology, enables the screening of virtually every gene in the human genome and in many individuals.

``We are very pleased to be working with GlaxoSmithKline, a leader in the pharmaceutical research and development industry,`` said Toni Schuh, Ph.D., SEQUENOM`s President and Chief Executive Officer. ``SEQUENOM brings to this partnership the expertise and technology necessary to identify potential disease-related SNPs, which will lead to the design of new diagnostic and therapeutic applications. Our company has made great strides toward developing a genome-wide set of confirmed SNP assays and the partnership with GSK significantly strengthens these efforts.``

The collaboration will allow GSK access to SEQUENOM`s extensive SNP assay portfolio and related confirmation data which will aid the pharmaceutical company in determining relevant gene targets most likely to be associated with disease and adverse drug response. SEQUENOM designs and processes assays for SNP candidates for assay validation and SNP confirmation in human reference populations. Combining its sophisticated bioinformatics with SEQUENOM`s technology, GSK will select those SNP candidates with high potential value for genome-wide association studies. Approximately 2 million unconfirmed SNP candidates were placed into the public domain by The SNP Consortium. Results using SNPs that have been confirmed will be widely useful in a variety of research settings and should enable major advancements in medicine.

``The partnership with SEQUENOM represents an important step forward in GlaxoSmithKline`s overall pharmacogenetics strategy,`` said Allen Roses, MD, Senior Vice President of Genetics Research at GlaxoSmithKline. ``Using the extensive SNP mapping databases that have been created over the past two years will be fundamental for identification of susceptibility disease gene variants and pharmacogenetics. GSK will apply this assay system to develop disease-relevant targets and to create SNP Prints(SM)* to identify patients at risk of major adverse events. Our immediate goal is to establish a SNP assay portfolio covering all SNPs that have been confirmed within this program by the end of 2001 for routine in-house use. We are confident that SEQUENOM can complete a project of this magnitude within our timelines, and utilize their technology to enable rapid use of whole genome SNP mapping.``

This study requires the use of a large quantity of oligonucleotides. To ensure quality, the oligonucleotides will be analyzed using SEQUENOM`s SpectroCHECK(TM) Oligo Quality Control System.

SNPs are the most common and simple form of genetic variation and represent the origin of most differences among individuals, including predisposition to disease and variations in drug efficacy and response. By comparing patterns and frequencies of SNPs in patients and in controls, researchers can identify associations between SNPs and particular diseases. SNP analysis, including full genome screens, is expected to play an essential role in the future of healthcare applications.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world`s leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GSK on the World Wide Web at www.gsk.com.

About SEQUENOM

SEQUENOM is a genomics company with the tools, information and strategies for determining the medical impact of genes and genetic variations. Utilizing a novel population genetics approach, SEQUENOM is systematically identifying potential disease-related genes that affect the most significant portions of the overall population. This approach is possible due to the accuracy and unique specificity of the Company`s MassARRAY system, which is largely accepted as the most powerful high-throughput screening technology in the industry. By focusing on disease genes with a broad population impact, SEQUENOM expects to play a critical role in bringing new therapeutic products to the market while maximizing the return on drug development.

SNP Prints(SM) is GSK`s proprietary system that defines the exact order, location and combination of SNP differences along the genome.
All statements in this press release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for SEQUENOM from those projected. Those factors include risks and uncertainties relating to successful completion of the SNP assay portfolio, technological approaches of SEQUENOM and its collaborators and competitors, product development, manufacturing, market acceptance, cost and pricing of SEQUENOM products, dependence on collaborative partners and commercial customers, successful performance under collaborative and commercial agreements including the present agreement with GSK, competition, the intellectual property of others, patent protection and other risk factors discussed from time to time in SEQUENOM`s reports and filings with the Securities and Exchange Commission, including SEQUENOM`s Annual Report on Form 10-K for the year ended December 31, 2000 and most recent Quarterly Report on form 10-Q. SEQUENOM expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in SEQUENOM`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

SOURCE: SEQUENOM, Inc.

[de Vega]

...wieso heute rennen? Die rennen doch schon
seit Frühjahr 2000.

[Börse2010]

Sequenom wird wieder kommen. So ca. auf 13$ bis Dez. 2001.

[NYSEBUY]

@Lassevegas

Danke für den Tip !!

Bin heute morgen rein zu 9,50